Home › Companies › Krystal Biotech, Inc. › 2025-2026
Compiled from SEC Form N-PX filings and Krystal Biotech, Inc.’s Form 8-K, filed May 20, 2026 (Item 5.07 on EDGAR). Page generated October 14, 2026.
Meeting of May 15, 2026: 5 items on Krystal Biotech, Inc.’s Form 8-K, filed May 20, 2026: 2 approved · 3 without a stated outcome.
None.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Explore Krystal Biotech, Inc. in the interactive database Compare manager voting policies
These tallies are Krystal Biotech, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 20, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Krish S. Krishnan | 23,802,920 | -- | -- | 3,079,194 | 1,581,473 | 89% | Not verified | — |
| Elect Director: Christopher Mason | 22,581,854 | -- | -- | 4,300,260 | 1,581,473 | 84% | Not verified | — |
| 2. Ratification of Appointment of Independent Registered Public Accounting Firm | 28,443,155 | 15,434 | 4,998 | -- | -- | 99.9% | Approved | — |
| 3. Non-Binding, Advisory Vote on Named Executive Officer Compensation | 25,679,318 | 1,195,788 | 7,008 | -- | 1,581,473 | 96% | Approved | — |
| 4. Non-Employee Director Compensation Policy The Company's unaffiliated stockholders (i.e., excluding the members of the the Company's board of directors and the defendants in the litigation entitled Corbin v | 21,374,021 | 2,349,550 | 3,158,543 | -- | 1,581,473 | 90% | Not verified | — |
Source: Krystal Biotech, Inc., Form 8-K, filed with the SEC on May 20, 2026 — read the filing on EDGAR.
Each item below shows how the 371 asset managers that disclosed a Krystal Biotech, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 7 wordings of this item as funds reported it.
84% Majority: yes · of votes cast
Description as filed by funds: Election of Class III Directors: Christopher Mason
Krystal Biotech, Inc.’s own tally for this item (“Elect Director: Christopher Mason”): 22,581,854 for, 4,300,260 withheld, per its Form 8-K filed May 20, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 84% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 105 asset managers below reported 11,055,090 for, 1,586,679 withheld, 117,825 abstained, 18,548 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 3,581,066 | 0 | 0 | 0 | For |
| Vanguard | 2,684,367 | 0 | 15 | 0 | For |
| BlackRock | 2,160,367 | 0 | 0 | 0 | For |
| Capital Group | 755,181 | 0 | 0 | 0 | For |
| State Street | 1,684 | 0 | 0 | 694,945 | Withhold |
| T. Rowe Price | 373,846 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 349,291 | 0 | 0 | 0 | For |
| First Trust | 0 | 0 | 0 | 349,271 | Withhold |
| Charles Schwab | 211,339 | 0 | 0 | 0 | For |
| Invesco | 188,698 | 0 | 0 | 0 | For |
| Franklin Custodian Funds | 150,000 | 0 | 0 | 0 | For |
| TIAA | 93,104 | 0 | 0 | 0 | For |
| WILLIAM BLAIR FUNDS | 0 | 0 | 0 | 91,520 | Withhold |
| Voya | 67,317 | 0 | 0 | 0 | For |
| Equitable | 43,274 | 0 | 0 | 20,060 | Mixed |
| NEW ECONOMY FUND | 62,845 | 0 | 0 | 0 | For |
| Jackson National | 0 | 0 | 58,432 | 0 | Abstain |
| Dimensional | 0 | 0 | 0 | 51,803 | Withhold |
| Janus Detroit Street Trust | 0 | 0 | 0 | 48,180 | Withhold |
| Columbia Threadneedle | 44,121 | 0 | 0 | 0 | For |
| Nuveen | 43,771 | 0 | 0 | 0 | For |
| John Hancock | 6,160 | 0 | 29,481 | 0 | Mixed |
| Victory Capital | 0 | 0 | 0 | 34,820 | Withhold |
| Lincoln Financial | 1,261 | 0 | 0 | 27,691 | Withhold |
| Pacific Life | 26,851 | 0 | 0 | 0 | For |
Showing the 25 largest of 105 asset managers. See all 105 in the interactive database.
Combines 7 wordings of this item as funds reported it.
89% Majority: yes · of votes cast
Description as filed by funds: Election of Class III Directors: Krish S. Krishnan
Krystal Biotech, Inc.’s own tally for this item (“Elect Director: Krish S. Krishnan”): 23,802,920 for, 3,079,194 withheld, per its Form 8-K filed May 20, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 89% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 105 asset managers below reported 11,716,487 for, 925,287 withheld, 117,820 abstained, 18,548 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 3,581,066 | 0 | 0 | 0 | For |
| Vanguard | 2,680,656 | 0 | 10 | 3,715 | For |
| BlackRock | 2,160,367 | 0 | 0 | 0 | For |
| Capital Group | 755,181 | 0 | 0 | 0 | For |
| State Street | 695,716 | 0 | 0 | 913 | For |
| T. Rowe Price | 373,846 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 349,291 | 0 | 0 | 0 | For |
| First Trust | 0 | 0 | 0 | 349,271 | Withhold |
| Charles Schwab | 211,339 | 0 | 0 | 0 | For |
| Invesco | 188,698 | 0 | 0 | 0 | For |
| Franklin Custodian Funds | 150,000 | 0 | 0 | 0 | For |
| TIAA | 93,104 | 0 | 0 | 0 | For |
| WILLIAM BLAIR FUNDS | 0 | 0 | 0 | 91,520 | Withhold |
| Voya | 0 | 0 | 0 | 67,317 | Withhold |
| Equitable | 43,274 | 0 | 0 | 20,060 | Mixed |
| NEW ECONOMY FUND | 62,845 | 0 | 0 | 0 | For |
| Jackson National | 0 | 0 | 58,432 | 0 | Abstain |
| Dimensional | 0 | 0 | 0 | 51,803 | Withhold |
| Janus Detroit Street Trust | 0 | 0 | 0 | 48,180 | Withhold |
| Columbia Threadneedle | 44,121 | 0 | 0 | 0 | For |
| Nuveen | 43,771 | 0 | 0 | 0 | For |
| John Hancock | 6,160 | 0 | 29,481 | 0 | Mixed |
| Victory Capital | 0 | 0 | 0 | 34,820 | Withhold |
| Lincoln Financial | 18,007 | 0 | 0 | 10,945 | Mixed |
| Pacific Life | 26,851 | 0 | 0 | 0 | For |
Showing the 25 largest of 105 asset managers. See all 105 in the interactive database.
Combines 11 wordings of this item as funds reported it.
96% Approved · of votes cast
Description as filed by funds: Approval of the compensation of the Company's named executive officers, on a non-binding, advisory basis.
Krystal Biotech, Inc.’s own tally for this item (“3. Non-Binding, Advisory Vote on Named Executive Officer Compensation”): 25,679,318 for, 1,195,788 against — passed, per its Form 8-K filed May 20, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal Three: Non-Binding, Advisory Vote on Named Executive Officer Compensation The Company's stockholders approved, on an advisory (non-binding) basis, the compensation of the Company's named executive officers for the fiscal year ended December 31, 2025, as disclosed in the Company's proxy sta…”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 3,581,066 | 0 | 0 | 0 | For |
| Vanguard | 2,684,379 | 3 | 0 | 0 | For |
| BlackRock | 2,160,367 | 0 | 0 | 0 | For |
| Capital Group | 0 | 755,181 | 0 | 0 | Against |
| State Street | 696,266 | 363 | 0 | 0 | For |
| T. Rowe Price | 373,846 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 349,291 | 0 | 0 | 0 | For |
| First Trust | 349,271 | 0 | 0 | 0 | For |
| Charles Schwab | 211,339 | 0 | 0 | 0 | For |
| Invesco | 188,698 | 0 | 0 | 0 | For |
| Franklin Custodian Funds | 150,000 | 0 | 0 | 0 | For |
| TIAA | 93,104 | 0 | 0 | 0 | For |
| WILLIAM BLAIR FUNDS | 91,520 | 0 | 0 | 0 | For |
| Voya | 67,317 | 0 | 0 | 0 | For |
| Equitable | 63,334 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 0 | 62,845 | 0 | 0 | Against |
| Jackson National | 58,432 | 0 | 0 | 0 | For |
| Dimensional | 51,803 | 0 | 0 | 0 | For |
| Janus Detroit Street Trust | 48,180 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 44,121 | 0 | 0 | 0 | For |
| Nuveen | 43,771 | 0 | 0 | 0 | For |
| John Hancock | 35,641 | 0 | 0 | 0 | For |
| Victory Capital | 34,820 | 0 | 0 | 0 | For |
| Lincoln Financial | 28,952 | 0 | 0 | 0 | For |
| Pacific Life | 26,851 | 0 | 0 | 0 | For |
Fund voting reports, all 105 managers: 11,922,282 for, 831,534 against, 4,676 abstained, 18,548 not voted, 54 mixed. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 4,310,729 | 0 | 0 | 0 | For |
| Avoro Capital Advisors LLC | 2,542,298 | 0 | 0 | 0 | For |
| BlackRock | 849,050 | 11,386 | 0 | 0 | For |
| Capital Group | 0 | 823,759 | 0 | 0 | Against |
| Redmile Group, LLC | 673,505 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 617,871 | 0 | 0 | 0 | For |
| Hood River Capital Management LLC | 565,170 | 0 | 0 | 0 | For |
| T. Rowe Price | 510,357 | 0 | 0 | 0 | For |
| Frazier Life Sciences Management, L.P. | 481,307 | 0 | 0 | 0 | For |
| State Street | 436,182 | 4,910 | 0 | 0 | For |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | 319,160 | 0 | 0 | 0 | For |
| Charles Schwab | 241,202 | 0 | 0 | 0 | For |
| Vanguard | 216,894 | 0 | 0 | 0 | For |
| Invesco | 201,686 | 13 | 0 | 0 | For |
| Soleus Capital Management, L.P. | 201,001 | 0 | 0 | 0 | For |
| FRANKLIN ADVISERS INC | 175,358 | 0 | 0 | 0 | For |
| Northern Trust | 164,495 | 2,506 | 0 | 0 | For |
| PRINCIPAL GLOBAL INVESTORS | 161,116 | 0 | 0 | 0 | For |
| Woodline Partners LP | 150,616 | 0 | 0 | 0 | For |
| Nuveen | 141,590 | 0 | 0 | 0 | For |
| Janus Henderson | 112,930 | 0 | 0 | 0 | For |
| PICTET ASSET MANAGEMENT SA | 108,737 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 101,850 | 0 | 0 | 0 | For |
| Voya | 97,545 | 0 | 0 | 0 | For |
| S SQUARED TECHNOLOGY, LLC | 86,215 | 0 | 0 | 0 | For |
Institutional-manager reports, all 289 managers: 14,957,957 for, 1,095,910 against, 17 not voted. Showing the 25 largest; see all in the interactive database.
Combines 4 wordings of this item as funds reported it.
90% Majority: yes · of votes cast
Description as filed by funds: Approval of the Company's Non- Employee Director Compensation Policy.
Krystal Biotech, Inc.’s own tally for this item (“4. Non-Employee Director Compensation Policy The Company's unaffiliated stockholders (i.e., excluding the members of the the Company's board of directors and the defendants in the litigation entitled Corbin v”): 21,374,021 for, 2,349,550 against, per its Form 8-K filed May 20, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 90% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 3,581,066 | 0 | 0 | 0 | For |
| Vanguard | 2,680,646 | 3,724 | 11 | 0 | For |
| BlackRock | 2,160,367 | 0 | 0 | 0 | For |
| Capital Group | 0 | 755,181 | 0 | 0 | Against |
| State Street | 696,408 | 221 | 0 | 0 | For |
| T. Rowe Price | 373,846 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 349,291 | 0 | 0 | 0 | For |
| First Trust | 349,271 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 211,339 | 0 | 0 | Against |
| Invesco | 188,698 | 0 | 0 | 0 | For |
| Franklin Custodian Funds | 0 | 150,000 | 0 | 0 | Against |
| TIAA | 93,104 | 0 | 0 | 0 | For |
| WILLIAM BLAIR FUNDS | 91,520 | 0 | 0 | 0 | For |
| Voya | 67,317 | 0 | 0 | 0 | For |
| Equitable | 63,334 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 0 | 62,845 | 0 | 0 | Against |
| Jackson National | 58,432 | 0 | 0 | 0 | For |
| Dimensional | 51,803 | 0 | 0 | 0 | For |
| Janus Detroit Street Trust | 48,180 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 44,121 | 0 | 0 | 0 | For |
| Nuveen | 43,771 | 0 | 0 | 0 | For |
| John Hancock | 35,641 | 0 | 0 | 0 | For |
| Victory Capital | 34,820 | 0 | 0 | 0 | For |
| Lincoln Financial | 28,952 | 0 | 0 | 0 | For |
| Pacific Life | 26,851 | 0 | 0 | 0 | For |
Fund voting reports, all 105 managers: 11,508,034 for, 1,250,448 against, 11 abstained, 18,548 not voted. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 481,307 | 0 | 0 | 0 | For |
| Granite Investment Partners, LLC | 18,218 | 0 | 0 | 0 | For |
| ZACKS INVESTMENT MANAGEMENT | 13,774 | 0 | 0 | 0 | For |
| Erste Asset Management GmbH | 8,700 | 0 | 0 | 0 | For |
| Janney Montgomery Scott LLC | 0 | 4,369 | 0 | 0 | Against |
| Vident Advisory, LLC | 1,481 | 0 | 0 | 0 | For |
| Sound View Wealth Advisors Group, LLC | 1,392 | 0 | 0 | 0 | For |
| Royal Capital Wealth Management, LLC | 278 | 0 | 0 | 0 | For |
| L2 Asset Management, LLC | 139 | 0 | 0 | 0 | For |
| UNITED CAPITAL FINANCIAL ADVISORS, LLC | 70 | 0 | 0 | 0 | For |
| Boltwood Capital Management | 58 | 0 | 0 | 0 | For |
| AUGUSTINE ASSET MANAGEMENT INC | 29 | 0 | 0 | 0 | For |
| Summit Trail Advisors, LLC | 11 | 0 | 0 | 0 | For |
| IMA Advisory Services, Inc. | 10 | 0 | 0 | 0 | For |
| Keel Point, LLC | 9 | 0 | 0 | 0 | For |
| Biltmore Family Office, LLC | 5 | 0 | 0 | 0 | For |
| Waverly Advisors, LLC | 5 | 0 | 0 | 0 | For |
| Naviter Wealth, LLC | 2 | 0 | 0 | 0 | For |
| Performance Wealth Partners, LLC | 1 | 0 | 0 | 0 | For |
| White Lighthouse Investment Management Inc. | 1 | 0 | 0 | 0 | For |
Institutional-manager reports, all 20 managers: 525,490 for, 4,369 against.
Combines 3 wordings of this item as funds reported it.
99.9% Approved · of votes cast
Description as filed by funds: TO RATIFY THE APPOINTMENT OF KPMG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR OUR FISCAL YEAR ENDING DECEMBER 31, 2026.
Krystal Biotech, Inc.’s own tally for this item (“2. Ratification of Appointment of Independent Registered Public Accounting Firm”): 28,443,155 for, 15,434 against — passed, per its Form 8-K filed May 20, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal Two: Ratification of Appointment of Independent Registered Public Accounting Firm The Company's stockholders ratified the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 109 asset managers below reported 12,758,624 for, 10,466 against, 4,676 abstained, 18,548 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 3,581,066 | 0 | 0 | 0 | For |
| Vanguard | 2,684,382 | 0 | 0 | 0 | For |
| BlackRock | 2,160,367 | 0 | 0 | 0 | For |
| Capital Group | 755,181 | 0 | 0 | 0 | For |
| State Street | 696,629 | 0 | 0 | 0 | For |
| T. Rowe Price | 373,846 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 349,291 | 0 | 0 | 0 | For |
| First Trust | 349,271 | 0 | 0 | 0 | For |
| Charles Schwab | 211,339 | 0 | 0 | 0 | For |
| Invesco | 188,698 | 0 | 0 | 0 | For |
| Franklin Custodian Funds | 150,000 | 0 | 0 | 0 | For |
| TIAA | 93,104 | 0 | 0 | 0 | For |
| WILLIAM BLAIR FUNDS | 91,520 | 0 | 0 | 0 | For |
| Voya | 67,317 | 0 | 0 | 0 | For |
| Equitable | 63,334 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 62,845 | 0 | 0 | 0 | For |
| Jackson National | 58,432 | 0 | 0 | 0 | For |
| Dimensional | 51,803 | 0 | 0 | 0 | For |
| Janus Detroit Street Trust | 48,180 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 44,121 | 0 | 0 | 0 | For |
| Nuveen | 43,771 | 0 | 0 | 0 | For |
| John Hancock | 35,641 | 0 | 0 | 0 | For |
| Victory Capital | 34,820 | 0 | 0 | 0 | For |
| Lincoln Financial | 28,952 | 0 | 0 | 0 | For |
| Pacific Life | 26,851 | 0 | 0 | 0 | For |
Showing the 25 largest of 109 asset managers. See all 109 in the interactive database.
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 29,437,000 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 12.17% |
| 2 | Vanguard | 9.12% |
| 3 | BlackRock | 7.34% |
| 4 | Capital Group | 2.57% |
| 5 | State Street | 2.37% |
| 6 | T. Rowe Price | 1.27% |
| 7 | Manager Directed Portfolios | 1.19% |
| 8 | First Trust | 1.19% |
| 9 | Charles Schwab | 0.72% |
| 10 | Invesco | 0.64% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 14.64% |
| 2 | Avoro Capital Advisors LLC | 8.64% |
| 3 | BlackRock | 2.92% |
| 4 | Capital Group | 2.80% |
| 5 | Redmile Group, LLC | 2.29% |
| 6 | GEODE CAPITAL MANAGEMENT, LLC | 2.10% |
| 7 | Hood River Capital Management LLC | 1.92% |
| 8 | T. Rowe Price | 1.73% |
| 9 | Frazier Life Sciences Management, L.P. | 1.64% |
| 10 | State Street | 1.50% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| FMR (Fidelity) | 14.86% | 13F |
| FMR LLC | 14.58% | DEF14A |
| BlackRock | 13.39% | 13F |
| Krish S. Krishnan | 11.51% | 13G |
| Vanguard Group | 9.44% | 13F |
| Avoro Capital Advisors LLC | 8.72% | DEF14A |
| Suma M. Krishnan | 5.65% | DEF14A |
| State Street | 4.47% | 13F |
| T. Rowe Price | 1.65% | 13F |
| Dimensional Fund Advisors | 1.59% | 13F |
Percentages above are of 29,437,000 shares outstanding, as reported by Krystal Biotech, Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Krystal Biotech, Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on October 14, 2026; a live search always shows the current data.
At Krystal Biotech, Inc.'s shareholder meeting held May 15, 2026, in the 2025-2026 proxy season, 371 asset managers reported how they voted on 5 ballot items in their SEC Form N-PX filings, covering 2,257 separate fund positions. On the most widely held item on that ballot — Approval of the compensation of the Company's named executive officers, on a non-binding… — Krystal Biotech, Inc.'s filing reports the proposal as approved, with 96% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Krystal Biotech, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 20, 2026.
Krystal Biotech, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).
Download data (CSV): ballot items · votes by manager · column guide.